Prohibitive Cost of HIV/Aids Therapy in the United States
Bibliographic Data
| ID | 15745348 |
|---|---|
| Authors | Jennifer Cohn (0000-0002-3446-7982, Hospital of the University of Pennsylvania, corresponding author) |
| Year | 2009 |
| Volume | 11 |
| Issue | 7 |
| Pages | 492-497 |
| Publication date | 2009-07-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The AMA Journal of Ethic (JOURNAL) |
| Journal identifiers | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/virtualmentor.2009.11.7.ccas1-0907 |
| PMID | 23199380 |
| OpenAlex | W167790157 |
| Language | EN |
Case Miss Brown had recently been diagnosed with HIV/AIDS and was a new patient in Dr. Chen’s infectious diseases clinic. When going over her chart, he noted that her CD4 count was below 350, the threshold for beginning antiretroviral treatment, according to U.S. care standards. Dr. Chen counseled Miss Brown to begin treatment as soon as possible, and she subsequently met with a medication counselor to discuss starting the highly active antiretroviral therapy (HAART)
Antiretroviral therapy · Family medicine · Human immunodeficiency virus (HIV · Viral load · HIV/AIDS Research and Interventions · Medicine · Pediatrics
| Highly cited | No |
|---|